COVID-19 Infection | Norton Healthcare

Indication: COVID-19 Infection

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

Cancer patients

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Telios Pharma, Inc.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.